FX.co ★ Cartesian's Descartes-08 Granted Rare Pediatric Disease Designation By FDA To Treat JDM

Cartesian Therapeutics, Inc. (Ticker: RNAC), a clinical-stage biotechnology company innovating mRNA cell therapies for autoimmune diseases, announced on Monday that the U.S. Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation to their therapy, Descartes-08, for the treatment of juvenile dermatomyositis (JDM).

The company mentioned that the Investigational New Drug (IND) application for their Phase 2 pediatric basket study is set for submission by the end of the year.

Descartes-08, the leading mRNA cell therapy candidate by Cartesian, is an autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy specifically targeting B-cell maturation antigen (BCMA). Notably, this therapy is designed to be administered without the need for preconditioning chemotherapy and does not utilize integrating vectors.

Juvenile dermatomyositis (JDM) is a rare pediatric autoimmune disorder characterized by a distinctive skin rash and muscle inflammation. This condition affects multiple organ systems, including the joints, heart, lungs, kidneys, eyes, and gastrointestinal tract.

The FDA grants Rare Pediatric Disease Designation for severe and life-threatening diseases that primarily impact children aged 18 years or younger and affect fewer than 200,000 individuals in the United States.

Under the FDA's Rare Pediatric Disease Designation and Priority Review Voucher Program, if Descartes-08 is approved for treating JDM, Cartesian may be eligible to receive a priority review voucher. This voucher can be utilized to obtain an expedited review for a separate marketing application of another product.

Carsten Brunn, President and Chief Executive Officer of Cartesian, remarked, "By leveraging our innovative mRNA platform, we are dedicated to expanding the scope of cell therapy to benefit patients with autoimmune diseases. We are on schedule to file an Investigational New Drug application for a Phase 2 pediatric basket study that will focus on autoimmune indications in neurology and rheumatology, including JDM, by year-end."